These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25582363)

  • 1. [Analysis of the five-year effectiveness of highly active antiretroviral therapy among 200 HIV/AIDS patients in Jiangsu province].
    Qiu T; Ding P; Liu X; Guo H; Fu G; Xu X; Huan X; Yang H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Nov; 48(11):947-52. PubMed ID: 25582363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Epidemiological characteristics of HIV/AIDS patients newly received highly active antiretroviral therapy during 2005-2013 in Jiangsu province].
    Qiu T; Ding P; Liu X; Xu J; Guo H; Fu G; Xu X; Huan X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Dec; 35(12):1320-3. PubMed ID: 25623446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on the mortality and risk factors among HIV/AIDS patients receiving antiretroviral therapy in Xinjiang Uygur Autonomous Region].
    Ni M; Chen X; Hu X; Ma Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Nov; 48(11):953-8. PubMed ID: 25582364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A retrospective cohort study on survival time of AIDS death cases receiving Antiretroviral Therapy and related factors].
    Hao L; Zhu X; Wang G; Lin B; Qian Y; Tao X; Hu J; Yang X; Kang D
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Jun; 48(6):466-70. PubMed ID: 25219434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of Qiling Decoction combined HAART on expression levels of Treg cells and Th17 in HIV/AIDS patients].
    Xu WF; Wu Y; Pan GS; Zhong JP; Lan SB; Chen XF; Lu QQ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Feb; 34(2):157-61. PubMed ID: 24672938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.
    Anastos K; Barrón Y; Miotti P; Weiser B; Young M; Hessol N; Greenblatt RM; Cohen M; Augenbraun M; Levine A; Muñoz A;
    Arch Intern Med; 2002 Sep; 162(17):1973-80. PubMed ID: 12230420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the situation of antiretroviral therapy against HIV/AIDS in Henan province based on the CD4+ T cells count and virus load].
    Liu J; Cui WG; Sun GQ; Zhu XP; Tian SA; Sun DY; Yang WJ; Li N; Zhu Q; Wang Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Sep; 31(9):1013-6. PubMed ID: 21162867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region].
    Ni M; Chen X; Ma Y; Hu X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Sep; 36(9):971-5. PubMed ID: 26814865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
    García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative influence of age on CD4+ cell recovery after highly active antiretroviral therapy in naive HIV-1-infected patients with severe immunodeficiency.
    Micheloud D; Berenguer J; Bellón JM; Miralles P; Cosin J; de Quiros JC; Conde MS; Muñoz-Fernández MA; Resino S
    J Infect; 2008 Feb; 56(2):130-6. PubMed ID: 18192020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.